Weis, Luiza N.
Tolaney, Sara M. http://orcid.org/0000-0002-5940-8671
Barrios, Carlos H. http://orcid.org/0000-0001-6021-667X
Barroso-Sousa, Romualdo http://orcid.org/0000-0002-1825-9876
Article History
Received: 3 March 2021
Accepted: 20 August 2021
First Online: 13 September 2021
Competing interests
: S.M.T. receives institutional research funding from AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Cyclacel, Odonate, and Seattle Genetics; has served as an advisor/consultant to AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Sanofi, Celldex, Paxman, Puma, Silverback Therapeutics, G1 Therapeutics, AbbVie, Anthenex, OncoPep, Outcomes4Me, Kyowa Kirin Pharmaceuticals, Daiichi-Sankyo, and Samsung Bioepsis Inc. C.H.B.: <b>Grants/research support</b>: (to the institution) Pfizer, Novartis, Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Roche/Genentech, Lilly, Sanofi, Taiho Pharmaceutical, Mylan, Merrimack, Merck, AbbVie, Astellas Pharma, BioMarin, Bristol-Myers Squibb, Daiichi Sankyo, Abraxis Biosciences, AB Science, Asana Biosciences, Medivation, Exelixis, ImClone Systems, LEO Pharma, Millennium, Merck KGaA, Shanghai Henlius Biotech, Polyphor, PharmaMar. <b>Ownership or Stocks:</b> Biomarker, Tummi, MEDSir. <b>Advisory Boards and Consulting</b>: Boehringer-Ingelheim, GSK, Novartis, Pfizer, Roche/Genentech, Eisai, Bayer, MSD, AstraZeneca, Zodiac, Lilly, Sanofi. R.B-S. has served as an advisor/consultant to Eli Lilly, Merck Sharp and Dohme, and Roche and has received honoraria from Bard Acess, Bristol-Myers Squib, Libbs, Eli Lilly, Novartis, Pfizer, Roche, Zodiac and travel accommodations or expenses from Roche and Daiichi-Sankyo. The remaining author declares no competing interests.